Medicinal chemistry publication describing novel SSRI drug discovery research

We are very pleased to be able to share the recent publication published in Bioorganic & Medicinal Chemistry Letters about presenting SSRI drug discovery research performed in collaboration with Acadia Pharmaceuticals.

SSRIs (Selective Serotonin Reuptake Inhibitors) is a class of drugs which is widely used for treating common psychiatric diseases such as major depression and includes well-known drugs such as Prozac (Fluoxetine), Zoloft (Sertraline) and Lexapro (Escitalopram). Despite their importance, this class of drugs have limitations, for example many major depression patients (up to 40%) do not receive adequate relief of their symptoms.

There are clinical data showing that by combining an SSRIs with a second drug that blocks 5-HT2A receptors, for example Pimavanserin, can give a better antidepressant effect. Described in this medicinal chemistry article is a research program with the goal of finding a new SSRI with the potential for use as a combination-treatment together with Pimavanserin.

Back